Sidley represented ADARx Pharmaceuticals, Inc., a clinical-stage biotechnology company developing RNA-targeting therapeutics, in its US$46 million Series B-1 financing. The proceeds from the financing will be used to advance ADARx’s proprietary RNA-targeting platform. ADARx has a growing pipeline of RNA-targeting therapeutics for treating diseases across a range of areas.
The Sidley team was led by James Lu (Emerging Companies and Venture Capital) and Feifei Bian (M&A), and included Pan Chen (M&A), Marie Allison (Private Equity), and James Mendenhall (Global Arbitration, Trade and Advocacy).
